Emerging anti-inflammatory drugs for atherosclerosis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Emerging Drugs

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728214.2013.801453PMID 23675745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cited by this paper
• Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield

  2013cited by this paper
• Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial.

  2013cited by this paper
• Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials.

  2012influential reference
• Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

  2012cited by this paper
• A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models.

  2012cited by this paper
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Phospholipase A2 enzymes and the risk of atherosclerosis.

  2012influential reference
• Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

  2012cited by this paper
• Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial

  2012cited by this paper
• 15 Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study)

  2011cited by this paper
• Anti-inflammatory therapeutics for the treatment of atherosclerosis

  2011influential reference
• Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region.

  2011cited by this paper
• AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

  2011cited by this paper
• Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.

  2011influential reference
• Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).

  2011cited by this paper
• Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

  2010cited by this paper
• Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome

  2010cited by this paper
• Pleiotropic effects of statins. - Basic research and clinical perspectives -.

  2010cited by this paper
• Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.

  2010influential reference
• Lp-PLA(2) and risk of atherosclerotic vascular disease.

  2010cited by this paper
• Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment

  2010cited by this paper
• Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans.

  2009cited by this paper
• Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease

  2009cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• LA-419, a nitric-oxide donor for the treatment of cardiovascular disorders.

  2009cited by this paper
• Inflammation in atherosclerosis: from pathophysiology to practice.

  2009cited by this paper
• Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)

  2009cited by this paper
• Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

  2009cited by this paper
• Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist.

  2008cited by this paper
• Biology of Secretory Phospholipase A2

  2008cited by this paper
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

  2008cited by this paper
• Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

  2008cited by this paper
• Targeting adhesion molecules in cardiovascular disorders.

  2008cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease

  2008cited by this paper
• Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Chemokines in Atherosclerosis , Thrombosis , and Vascular Biology Series Editor : Christian Weber Chemokines in Atherosclerosis An Update

  2008cited by this paper
• Leukotrienes.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Mechanisms of disease: Leukotrienes

  2007cited by this paper
• Vascular Biomarkers and Surrogates in Cardiovascular Disease

  2006cited by this paper
• Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2

  2006cited by this paper
• Vascular Biomarkers and Surrogates in Cardiovascular Disease

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• C-reactive protein levels and outcomes after statin therapy.

  2005influential reference
• Association Between 5-Lipoxygenase Expression and Plaque Instability in Humans

  2005cited by this paper
• Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population.

  2005cited by this paper
• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

  2005cited by this paper
• Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.

  2005cited by this paper
• Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells

  2004cited by this paper
• Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

  2004cited by this paper
• Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

  2004cited by this paper
• Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells.

  2004cited by this paper
• Intensive statin therapy--a sea change in cardiovascular prevention.

  2004cited by this paper
• Anti-inflammatory properties of statins.

  2004cited by this paper
• From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation.

  2004influential reference
• The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke

  2004cited by this paper
• Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?

  2004cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004cited by this paper
• Declines in Mortality From Acute Myocardial Infarction in Successive Incidence and Birth Cohorts of Patients With Rheumatoid Arthritis

  2004cited by this paper
• Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

  2004cited by this paper
• Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis

  2003cited by this paper
• Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro

  2001cited by this paper
• Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

  2001cited by this paper
• Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

  2001cited by this paper
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

  2000cited by this paper
• Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.

  1999cited by this paper
• Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein

  1999cited by this paper
• Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

  1998cited by this paper
• Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

  1998cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Monocyte chemoattractant protein-1 in human atheromatous plaques.

  1991cited by this paper
• Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

  1990cited by this paper
• American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

  year unknowncited by this paper

• Pla2g7 regulates bone homeostasis via Alox12/12-HETE/Gpr31 signaling axis

  2025cites this paper
• Macroalgal Proteins: A Review

  2022cites this paper
• Effects of nanoparticle-mediated delivery of pitavastatin on atherosclerotic plaques in ApoE-knockout mice and THP-1-derived macrophages

  2020cites this paper
• Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence

  2020cites this paper
• Polymeric Vector-Mediated Targeted Delivery of Anti-PAK1 siRNA to Macrophages for Efficient Atherosclerosis Treatment.

  2019cites this paper
• Translating Molecular Imaging of the Vulnerable Plaque—a Vulnerable Project?

  2018cites this paper
• Ganoderma Triterpenoids Exert Antiatherogenic Effects in Mice by Alleviating Disturbed Flow-Induced Oxidative Stress and Inflammation

  2018cites this paper
• Repeated Measurements of Serum Concentrations of TNF‐alpha, Interleukin‐6, and Interleukin‐10 in the Evaluation of Internal Carotid Artery Stenosis Progression

  2017cites this paper
• Mutant CCL2 protein coating mitigates wear particle-induced bone loss in a murine continuous polyethylene infusion model.

  2017cites this paper
• Microarray-based bioinformatics analysis of the combined effects of SiNPs and PbAc on cardiovascular system in zebrafish.

  2017cites this paper
• Macrophage selective photodynamic therapy by meta‐tetra(hydroxyphenyl)chlorin loaded polymeric micelles: A possible treatment for cardiovascular diseases

  2017cites this paper
• Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis

  2017influential citation
• Repeated measurements of serum concentrations of TNF-alpha , interleukin-6 and interleukin-10 in evaluation of the internal carotid artery stenosis progression

  2017cites this paper
• The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis

  2017cites this paper
• SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.

  2016cites this paper
• RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.

  2016cites this paper
• Terapia con anticuerpos monoclonales en Cardiología y Medicina Interna

  2016cites this paper
• Patchouli alcohol attenuates experimental atherosclerosis via inhibiting macrophage infiltration and its inflammatory responses.

  2016cites this paper
• Celecoxib for the treatment of atherosclerosis

  2016cites this paper
• Anti-cytokine therapy for prevention of atherosclerosis.

  2016cites this paper
• Inflammatory markers and cardiometabolic diseases

  2015cites this paper
• Protective effects of quercetin and taraxasterol against H2O2-induced human umbilical vein endothelial cell injury in vitro

  2015cites this paper
• Effect of pioglitazone combined with simvastatin on the CD40-CD40 ligand system in rabbits with atherosclerosis.

  2015cites this paper
• Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

  2015cites this paper
• Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells

  2015cites this paper
• Eicosanoids and Aortic Aneurysm

  2015cites this paper
• Nuclear imaging to support anti-inflammatory drug discovery and development.

  2014cites this paper
• Improving lipid control following myocardial infarction

  2014cites this paper
• 99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice

  2014influential citation
• S-adenosylmethionine mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages.

  2014cites this paper
• Related articles

  2014cites this paper
• Update on selective treatments targeting neutrophilic inflammation in atherogenesis and atherothrombosis

  2013influential citation
• Inflammation and the heart – prime time for new therapeutic approaches

  2013cites this paper
• Development of a seaweed derived platelet activating factor acetylhydrolase (PAF-AH) inhibitory hydrolysate, synthesis of inhibitory peptides and assessment of their toxicity using the Zebrafish larvae assay.

  2013cites this paper